# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it has been award...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $15 pr...
Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $15 pr...
Drug-device combination leverages Biora's NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potentia...